FDA Approves Tividenofusp Alfa for Hunter Syndrome: First Enzyme Replacement Therapy for Neurologic Symptoms

Executive Brief

News Report

The News: FDA approves tividenofusp alfa for Hunter syndrome.
Clinical Win: First enzyme replacement therapy targeting neurologic symptoms in pediatric patients.
Target Specialty: Pediatrics, Genetics

Key Data at a Glance

Approval Date: March 25, 2026
Patient Population: Pediatric patients with Hunter syndrome
Average CSF HS Reduction: 91% at Week 24

The FDA has approved tividenofusp alfa (Avlayah) for the treatment of certain individuals with Hunter syndrome, also known as Mucopolysaccharidosis type II (MPS II). This approval, announced on March 25, 2026, marks a significant advancement in addressing the neurologic manifestations of this rare genetic disorder, which predominantly affects males and can lead to severe developmental challenges.

Clinical Context

Hunter syndrome is a rare X-linked lysosomal storage disorder caused by the deficiency of the enzyme iduronate-2-sulfatase, leading to the accumulation of glycosaminoglycans, particularly heparan sulfate, within lysosomes. This accumulation results in progressive damage to various organs, including the brain, heart, and skeletal system, and can severely impact cognitive and physical development. Current treatments primarily focus on managing symptoms rather than addressing the underlying enzymatic deficiency, leaving a significant gap in effective therapies for the neurologic complications associated with the condition. Tividenofusp alfa, administered via weekly intravenous infusion, is the first therapy specifically approved to target these neurologic manifestations, providing a potential new avenue for treatment in young patients before advanced neurologic impairment occurs.

Key Findings

The FDA approved tividenofusp alfa (Avlayah) for the treatment of neurologic manifestations of Hunter syndrome in pediatric patients weighing at least 5 kg [1].
The approval was based on a phase 1/2 trial that included 47 pediatric patients aged 3 months to 13 years, where the drug significantly reduced cerebrospinal fluid heparan sulfate levels [1].
At Week 24, patients treated with tividenofusp alfa showed an average decrease of 91% in cerebrospinal fluid heparan sulfate levels, with 93% of patients achieving levels below the upper limit of normal [1].

Safety & Tolerability

The drug's labeling includes a boxed warning for potential allergic reactions, including anaphylaxis, necessitating careful monitoring during administration [1].

What This Means for Clinical Practice

Tividenofusp alfa represents a critical advancement for clinicians managing pediatric patients with Hunter syndrome, particularly those who are presymptomatic or symptomatic but have not yet experienced advanced neurologic impairment. The significant reduction in cerebrospinal fluid heparan sulfate levels suggests that early intervention with this enzyme replacement therapy could potentially alter the disease trajectory and improve outcomes for affected children. Clinicians should consider integrating this therapy into their treatment plans for eligible patients, while remaining vigilant for possible allergic reactions during administration. The ongoing randomized clinical trial will further elucidate the long-term clinical benefits of this therapy, and its findings may shape future treatment guidelines for Hunter syndrome management.

Clinical Perspective

Workflow: Clinicians should evaluate young patients for eligibility for tividenofusp alfa treatment, especially those with early signs of neurologic impairment.

Economics: The introduction of this therapy may impact healthcare costs associated with long-term management of Hunter syndrome.

Patient Outcomes: Early intervention with tividenofusp alfa could lead to improved developmental and cognitive outcomes in affected children.

Editorial Team, Rare Disease

References

FDA — FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome

FDA Approves Tividenofusp Alfa for Hunter Syndrome: First Enzyme Replacement Therapy for Neurologic Symptoms

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Rare Disease in your inbox.

Related Drug Updates

FDA Approves Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency: Over 90% Survival Benefit

FDA Approves Yuviwel (navepegritide) for Achondroplasia: Weekly Injection to Enhance Growth in Pediatric Patients

FDA Approves Tividenofusp Alfa for Hunter Syndrome: Neurologic Manifestations Treatment

Verified HCP Portal